GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » Valuation Rank

WAVE Life Sciences (STU:1U5) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

WAVE Life Sciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » Valuation Rank
Comparable Companies
CLDX DYN LQDA SPRY OCUL ETNB VRDN ARDX IOVA IDYA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
WVE:USA 1U5:Germany
Address
7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
Website
https://www.wavelifesciences.com
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.